Pfizer Q3 Review - Vitamins-Minerals-Nutritionals Portfolio Continues To Grow Strong: ICICI Securities
Pfizer-BioNTech is yet to be approved by DCGI. 

Pfizer Q3 Review - Vitamins-Minerals-Nutritionals Portfolio Continues To Grow Strong: ICICI Securities

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Securities Report

Pfizer Ltd. reported an operationally strong performance in the quarter.

Revenue grew 10.3% YoY to Rs 6.0 billion (our estimate Rs 6.0 billion) as company is benefiting from its vitamins/minerals/nutrients portfolio in the current environment.

Ebitda margin jumped 840 basis points YoY to 33.2% (our estimate 29.8%) driven by lower selling general and administrative costs and adjusted profit after tax grew 25.2% YoY to Rs 1.4 billion (our estimate Rs 1.2 billion).

We remain positive on the company’s growth visibility with exposure only in domestic formulations and strong balance sheet with deep cash reserves.

Click on the attachment to read the full report:

ICICI Securities Pfizer Q3FY21 Result Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.